

NEXICLON XR - (EQ 0.17MG BASE,EQ 0.26MG BASE ; TABLET,EXTENDED RELEASE)

Generic Name	CLONIDINE	Innovator	Athena
Dosage	EQ 0.17MG BASE,EQ 0.26MG BASE ; TABLET,EXTENDED RELEASE	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	NEXICLON XR is a central alpha-adrenergic agonist indicated for: • Treatment of hypertension.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.